Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0JUCHZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
40410803 16B10-MMAF
|
|||||
| Synonyms |
16B10-MMAF
Click to Show/Hide
|
|||||
| Organization |
Instituto de Biología Molecular y Celular del Cáncer - CSIC.; CIBERONC.; IBSAL.; Catalan Institute of Oncology.; Institut d'Investigació Biomèdica de Bellvitge - IDIBELL - ONCOBELL.
|
|||||
| Drug Status |
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
16B10
|
Antibody Info | ||||
| Antigen Name |
Transforming growth factor alpha (TGFA)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin F
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Site-specific bioconjugation via a dibromomaleimidelinker (DBM)
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.05۪.03 nM
|
|||
| Method Description |
All cell lines were cultured at 37oC in a humidified atmosphere in the presence of 5% CO2 and 95% air in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FBS containing high glucose (4500 mg/liter) and antibiotics (penicillin 100 U/ml, streptomycin 100 ug/ml). Cells were tested for authenticity by STR at the Hematology Service of the University of Salamanca. NP29 and NP31 cells were obtained from patient samples by Dr. Gabriel Capellá. Cell proliferation experiments were conducted using a Z1 Coulter Particle Counter as described previously [28, 29]. Apoptosis and cell cycle analyses were performed as described [30]. The KRAS mutation status of genomic DNA isolated using TRIzol (Thermo Fisher Scientific) from Capan-1, IMIM-PC1, IMIM-PC2, SKPC1, NP29, and NP31 cell lines was analyzed with the KRAS Mutation Test v2 (LSR) on the Cobas® platform (Roche Diagnostics) by PCR using the Cobas® z 480 analyzer (Roche). The resulting data are presented in Supplementary Table 1.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | SKPC1 cells | CVCL_4054 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.15۪.04 nM
|
|||
| Method Description |
All cell lines were cultured at 37oC in a humidified atmosphere in the presence of 5% CO2 and 95% air in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FBS containing high glucose (4500 mg/liter) and antibiotics (penicillin 100 U/ml, streptomycin 100 ug/ml). Cells were tested for authenticity by STR at the Hematology Service of the University of Salamanca. NP29 and NP31 cells were obtained from patient samples by Dr. Gabriel Capellá. Cell proliferation experiments were conducted using a Z1 Coulter Particle Counter as described previously [28, 29]. Apoptosis and cell cycle analyses were performed as described [30]. The KRAS mutation status of genomic DNA isolated using TRIzol (Thermo Fisher Scientific) from Capan-1, IMIM-PC1, IMIM-PC2, SKPC1, NP29, and NP31 cell lines was analyzed with the KRAS Mutation Test v2 (LSR) on the Cobas® platform (Roche Diagnostics) by PCR using the Cobas® z 480 analyzer (Roche). The resulting data are presented in Supplementary Table 1.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic carcinoma | NP29 cells | CVCL_E3BR | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.32۪.08 nM
|
|||
| Method Description |
All cell lines were cultured at 37oC in a humidified atmosphere in the presence of 5% CO2 and 95% air in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FBS containing high glucose (4500 mg/liter) and antibiotics (penicillin 100 U/ml, streptomycin 100 ug/ml). Cells were tested for authenticity by STR at the Hematology Service of the University of Salamanca. NP29 and NP31 cells were obtained from patient samples by Dr. Gabriel Capellá. Cell proliferation experiments were conducted using a Z1 Coulter Particle Counter as described previously [28, 29]. Apoptosis and cell cycle analyses were performed as described [30]. The KRAS mutation status of genomic DNA isolated using TRIzol (Thermo Fisher Scientific) from Capan-1, IMIM-PC1, IMIM-PC2, SKPC1, NP29, and NP31 cell lines was analyzed with the KRAS Mutation Test v2 (LSR) on the Cobas® platform (Roche Diagnostics) by PCR using the Cobas® z 480 analyzer (Roche). The resulting data are presented in Supplementary Table 1.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
1.06۪.29 nM
|
|||
| Method Description |
All cell lines were cultured at 37oC in a humidified atmosphere in the presence of 5% CO2 and 95% air in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FBS containing high glucose (4500 mg/liter) and antibiotics (penicillin 100 U/ml, streptomycin 100 ug/ml). Cells were tested for authenticity by STR at the Hematology Service of the University of Salamanca. NP29 and NP31 cells were obtained from patient samples by Dr. Gabriel Capellá. Cell proliferation experiments were conducted using a Z1 Coulter Particle Counter as described previously [28, 29]. Apoptosis and cell cycle analyses were performed as described [30]. The KRAS mutation status of genomic DNA isolated using TRIzol (Thermo Fisher Scientific) from Capan-1, IMIM-PC1, IMIM-PC2, SKPC1, NP29, and NP31 cell lines was analyzed with the KRAS Mutation Test v2 (LSR) on the Cobas® platform (Roche Diagnostics) by PCR using the Cobas® z 480 analyzer (Roche). The resulting data are presented in Supplementary Table 1.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic carcinoma | NP31 cells | CVCL_E3BS | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.83۫.91 nM
|
|||
| Method Description |
All cell lines were cultured at 37oC in a humidified atmosphere in the presence of 5% CO2 and 95% air in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FBS containing high glucose (4500 mg/liter) and antibiotics (penicillin 100 U/ml, streptomycin 100 ug/ml). Cells were tested for authenticity by STR at the Hematology Service of the University of Salamanca. NP29 and NP31 cells were obtained from patient samples by Dr. Gabriel Capellá. Cell proliferation experiments were conducted using a Z1 Coulter Particle Counter as described previously [28, 29]. Apoptosis and cell cycle analyses were performed as described [30]. The KRAS mutation status of genomic DNA isolated using TRIzol (Thermo Fisher Scientific) from Capan-1, IMIM-PC1, IMIM-PC2, SKPC1, NP29, and NP31 cell lines was analyzed with the KRAS Mutation Test v2 (LSR) on the Cobas® platform (Roche Diagnostics) by PCR using the Cobas® z 480 analyzer (Roche). The resulting data are presented in Supplementary Table 1.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | IMIM-PC2 cells | CVCL_0345 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9.17ۮ.23 nM
|
|||
| Method Description |
All cell lines were cultured at 37oC in a humidified atmosphere in the presence of 5% CO2 and 95% air in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FBS containing high glucose (4500 mg/liter) and antibiotics (penicillin 100 U/ml, streptomycin 100 ug/ml). Cells were tested for authenticity by STR at the Hematology Service of the University of Salamanca. NP29 and NP31 cells were obtained from patient samples by Dr. Gabriel Capellá. Cell proliferation experiments were conducted using a Z1 Coulter Particle Counter as described previously [28, 29]. Apoptosis and cell cycle analyses were performed as described [30]. The KRAS mutation status of genomic DNA isolated using TRIzol (Thermo Fisher Scientific) from Capan-1, IMIM-PC1, IMIM-PC2, SKPC1, NP29, and NP31 cell lines was analyzed with the KRAS Mutation Test v2 (LSR) on the Cobas® platform (Roche Diagnostics) by PCR using the Cobas® z 480 analyzer (Roche). The resulting data are presented in Supplementary Table 1.
Click to Show/Hide
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | IMIM-PC1 cells | CVCL_4061 | ||
References
